

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**  
**Cardboard carton/ Secondary Packaging**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vetergesic Multidose, 0.3mg/ml solution for injection for dogs and cats  
Buprenorphine as buprenorphine hydrochloride

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Buprenorphine as buprenorphine hydrochloride 0.3 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

10 ml

**5. TARGET SPECIES**

Dogs and cats

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intravenous or intramuscular use.  
Shake well before use.  
Read the package leaflet before use.

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

<EXP {month/year}>  
Shelf life after first opening the immediate packaging: 28 days  
Once broached, use by ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

**11. SPECIAL STORAGE CONDITIONS**

Keep vial in outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only

**14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

Keep out of the sight and reach of children

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Ceva Animal Health Ltd  
Explorer House  
Mercury Park  
Wycombe Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom

**16. MARKETING AUTHORISATION NUMBER**

Vm 15052/4082

**17. MANUFACTURER’S BATCH NUMBER**

Batch> <Lot> or <BN> {number}.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS  
TYPE I AMBER GLASS VIAL /PRIMARY PACKAGING**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vetergesic Multidose, 0.3mg/ml solution for injection for dogs and cats.  
Buprenorphine hydrochloride

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Buprenorphine as buprenorphine hydrochloride 0.3mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 ml

**4. ROUTE(S) OF ADMINISTRATION**

i.m, i.v.

**5. WITHDRAWAL PERIOD**

**6. BATCH NUMBER**

Batch> <Lot> or <BN>

**7. EXPIRY DATE**

<EXP {month/year}>  
Once broached, use by:

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

Vetergesic Multidose, 0.3mg/ml solution for injection for dogs and cats  
Buprenorphine as buprenorphine hydrochloride

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

#### Marketing Authorisation Holder:

Ceva Animal Health Ltd  
Explorer House  
Mercury Park  
Wycombe Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom

#### Manufacturer responsible for batch release

LABIANA LIFE SCIENCES, S.A.  
C/ Venus, 26, Pol. Ind. Can Parellada, Terrassa, 08228 Barcelona, Spain

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vetergesic Multidose, 0.3mg/ml solution for injection for dogs and cats.  
Buprenorphine as buprenorphine hydrochloride.

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

1 ml solution for injection contains:

Active substance:

Buprenorphine	0.3 mg
as buprenorphine hydrochloride	0.324 mg

Excipient(s):

Chlorocresol	1.35 mg
as antimicrobial preservative	

Clear, colourless solution for injection.

### 4. INDICATION(S)

#### DOG

Post-operative analgesia.  
Potentiation of the sedative effects of centrally-acting agents.

#### CAT

Post-operative analgesia'

## 5. CONTRAINDICATIONS

Do not administer by the intrathecal or peridural route.  
Do not use pre-operatively for caesarian section.  
Do not use in animals with known hypersensitivity to the active substance or to any of the excipients

## 6. ADVERSE REACTIONS

Salivation, bradycardia, hypothermia, agitation, dehydration and miosis can occur in the dog, and rarely hypertension and tachycardia. Mydriasis and signs of euphoria (excessive purring, pacing, rubbing) commonly occur in cats and will usually resolve within 24 hours.

Buprenorphine may cause respiratory depression.

When used to provide analgesia, sedation is rarely seen, but may occur at dose levels higher than those recommended.

Local discomfort or pain at the injection site, resulting in vocalisation, may occur very rarely. The effect is normally temporary.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Dogs and cats.

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Shake well before use.

An appropriately graduated syringe must be used to allow accurate dosing.

Species	Route of Administration	Post-Operative Analgesia	Potential of Sedation
Dog	Intramuscular or intravenous injection	10-20 micrograms per kg (0.3-0.6ml per 10kg). For further pain relief, repeat if necessary after 3-4 hours with 10 microgram per kg or 5-6 hours with 20 microgram per kg.	10-20 micrograms per kg (0.3-0.6ml per 10kg).
Cat	Intramuscular or intravenous injection	10 – 20 microgram per kg (0.3 – 0.6ml per 10kg), repeated if necessary, once, after 1-2 hours.	---

## 9. ADVICE ON CORRECT ADMINISTRATION

While sedative effects are present by 15 minutes after administration, analgesic activity becomes apparent after approximately 30 minutes. To ensure that analgesia is present during surgery and immediately on recovery, the product should be administered pre-operatively as part of premedication. If additional analgesia is



subsequently required, this may be achieved by administration of further dose(s) of buprenorphine or concomitant use of a suitable injectable NSAID.

When administered for potentiation of sedation or as part of premedication, the dose of other centrally-acting agents, such as acepromazine or medetomidine, should be reduced. The reduction will depend on the degree of sedation required, the individual animal, the type of other agents included in premedication and how anaesthesia is to be induced and maintained. It may also be possible to reduce the amount of inhalational anaesthetic used.

## 10. WITHDRAWAL PERIOD

Not applicable

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

Shake well before use.

Do not use after expiry date stated on the label after EXP.

Shelf life after first opening the immediate packaging: 28 days.

## 12. SPECIAL WARNING(S)

### **Precautions:**

Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression.

In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk associated with the use of the product. The benefit: risk assessment for using the product should be made by the attending vet. Safety has not been fully evaluated in clinically compromised cats.

Buprenorphine should be used with caution in animals with impaired liver function, especially biliary tract disease, as the substance is metabolised by the liver and its intensity and duration of action may be affected in such animals.

The safety of buprenorphine has not been demonstrated in animals less than 7 weeks of age, therefore, use in such animals should be based on the risk: benefit assessment of the veterinarian.

Repeat administration earlier than the recommended repeat interval suggested in Section 4.9 is not recommended.

Long-term safety of buprenorphine in cats has not been investigated beyond 5 consecutive days of administration.

The effect of an opioid on head injury is dependent on the type and severity of the injury and the respiratory support supplied. The product should be used in accordance with the benefit:risk assessment of the attending veterinarian.

### **Pregnancy:**

Laboratory studies in rats have not produced any evidence of a teratogenic effect. However, these studies have shown post-implantation losses and early foetal deaths. These may have resulted from a reduction in parental body condition during gestation and in post-natal care owing to sedation of the mothers.

As reproductive toxicity studies have not been conducted in the target species, use only according to the benefit/risk assessment by the responsible veterinarian. The product should not be used pre-operatively in cases of Caesarean section, due to the risk of respiratory depression in the offspring periparturiently, and should only be used post-operatively with special care.

#### **Lactation:**

Studies in lactating rats have shown that, after intramuscular administration of buprenorphine, concentrations of unchanged buprenorphine in the milk equalled or exceeded that in the plasma. As it is likely that buprenorphine will be excreted in the milk of other species, use is not recommended during lactation. Use only according benefit: risk assessment by the responsible veterinarian.

#### **Interactions with other medicinal products and other forms of interaction**

Buprenorphine may cause some drowsiness, which may be potentiated by other centrally acting agents, including tranquillisers, sedatives and hypnotics.

It is recommended that buprenorphine is not used in conjunction with morphine or other opioid-type analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or butorphanol, although there is evidence in humans to indicate that therapeutic doses of buprenorphine do not reduce the analgesic efficacy of standard doses of an opioid agonist and that when buprenorphine is employed within the normal therapeutic range, standard doses of opioid agonist may be administered before the effects of the former have ended without compromising analgesia.

Buprenorphine has been used with acepromazine, alphaxalone/alphadalone, atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol, sevoflurane, thiopentone and xylazine. When used in combination with sedatives, depressive effects on heart rate and respiration may be augmented.

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

#### **User Safety and Warnings**

As buprenorphine has opioid-like activity, care should be taken to avoid self-injection. In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Following eye contamination or skin contact, wash thoroughly with cold running water. Seek medical advice if irritation persists.

Wash hands/affected area thoroughly after any accidental spillage.

#### **Overdosage**

In cases of overdosage, supportive measures should be instituted, and, if appropriate, naloxone or respiratory stimulants may be used.

When administered at overdose to dogs, buprenorphine may cause lethargy. At very high doses, bradycardia and miosis may be observed.

Naloxone may be of benefit in reversing reduced respiratory rate and respiratory stimulants such as Doxapram are also effective in man. Because of the prolonged duration of effect of buprenorphine in comparison to such drugs, they may need to be administered repeatedly or by continuous infusion. Volunteer studies in man have indicated that opiate antagonists may not fully reverse the effects of buprenorphine.

In toxicological studies of buprenorphine hydrochloride in dogs, biliary hyperplasia was observed after oral administration for one year at dose levels of 3.5mg/kg/day and above. Biliary hyperplasia was not observed following daily intramuscular

injection of dose levels up to 2.5mg/kg/day for 3 months. This is well in excess of any clinical dose regimen in the dog.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

October 2022

**15. OTHER INFORMATION**

**Presentation:**

Vetergesic Multidose is presented in 10 ml amber glass vials, with chlorobutyl rubber stopper, as sterile, clear, colourless, aqueous solution for injection. Each 1ml contains 0.3mg buprenorphine, as buprenorphine hydrochloride, in a 5% glucose solution. It also contains 1.35mg/ml chlorocresol, as antimicrobial preservative.


When the container is broached (opened) for the first time, using the in-use shelf life which is specified on this package insert, the date on which any product remaining in the container should be discarded should be worked out. This discard date should be written in the space provided on the label.

**Legal category**

POM-V

**Distributor:**

Ceva Animal Health Ltd  
Explorer House  
Mercury Park  
Wycombe Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom



Approved: 18 October 2022